Catalytic Metallodrugs: Substrate‐Selective Metal Catalysts as Therapeutics
- 21 August 2017
- journal article
- review article
- Published by Wiley in Chemistry – A European Journal
- Vol. 23 (57) , 14113-14127
Abstract
Metal complexes that catalyze inactivation and degradation of biomolecular targets can be developed into novel therapeutics (catalytic metallodrugs) against a variety of diseases. Despite recent advances in the field, a lack of substrate selectivity is a major hindrance to the development of catalytic metallodrugs for application in clinical practice. Improved targeting can minimize nonselective activity and the potential for side effects. Herein, we focus on recent developments toward novel metal catalysts that exhibit substrate selectivity against a variety of therapeutically relevant biomolecules. Design strategies for developing selective catalytic metallodrugs are also highlighted.Keywords
Funding Information
- National Institutes of Health (HL093446)
This publication has 259 references indexed in Scilit:
- Mixed-ligand Cu(II)–vanillin Schiff base complexes; effect of coligands on their DNA binding, DNA cleavage, SOD mimetic and anticancer activityEuropean Journal of Medicinal Chemistry, 2013
- Photoactivated DNA cleavage and anticancer activity of pyrenyl-terpyridine lanthanide complexesEuropean Journal of Medicinal Chemistry, 2012
- Organometallic Ruthenium and Iridium Transfer‐Hydrogenation Catalysts Using Coenzyme NADH as a CofactorAngewandte Chemie International Edition, 2012
- Organometallic Ruthenium and Iridium Transfer‐Hydrogenation Catalysts Using Coenzyme NADH as a CofactorAngewandte Chemie, 2012
- Mammalian cell transfection: the present and the futureAnalytical and Bioanalytical Chemistry, 2010
- Metallotherapeutics: Novel Strategies in Drug DesignChemistry – A European Journal, 2009
- G-quadruplex nucleic acids as therapeutic targetsCurrent Opinion in Chemical Biology, 2009
- Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?Drug Discovery Today, 2008
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic dataJournal of Pharmacokinetics and Biopharmaceutics, 1980